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It has been hypothesised that nonsyndromic cleft lip/palate (nsCL/P) and
cancer may share aetiological risk factors. Population studies have found in-
consistent evidence for increased incidence of cancer in nsCL/P cases, but
several genes (e.g., CDH1, AXIN2) have been implicated in the aetiologies of
both phenotypes. We aimed to evaluate shared genetic aetiology between
nsCL/P and oral cavity/oropharyngeal cancers (OC/OPC), which affect similar
anatomical regions. Using a primary sample of 5,048 OC/OPC cases and 5,450
controls of European ancestry and a replication sample of 750 cases and
336,319 controls from UK Biobank, we estimate genetic overlap using nsCL/P
polygenic risk scores (PRS) with Mendelian randomization analyses performed
to evaluate potential causal mechanisms. In the primary sample, we found
strong evidence for an association between a nsCL/P PRS and increased odds
of OC/OPC (per standard deviation increase in score, odds ratio [OR]: 1.09;
95% confidence interval [CI]: 1.04, 1.13; p= .000053). Although confidence
intervals overlapped with the primary estimate, we did not find confirmatory
evidence of an association between the PRS and OC/OPC in UK Biobank (OR
1.02; 95% CI: 0.95, 1.10; p= .55). Mendelian randomization analyses provided
evidence that major nsCL/P risk variants are unlikely to influence OC/OPC.
Our findings suggest possible shared genetic influences on nsCL/P and
OC/OPC.
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1 | INTRODUCTION
Nonsyndromic cleft lip/palate (nsCL/P) is a birth defect
characterised by lack of fusion of structures in the upper lip
and palate, with a complex aetiology influenced by both
genetic and environmental factors (Dixon, Marazita,
Beaty, & Murray, 2011; Mossey, Little, Munger, Dixon, &
Shaw, 2009). Evidence from epidemiological population‐
based studies that individuals with birth defects have in-
creased incidence of cancer (Bjørge, Cnattingius, Lie,
Tretli, & Engeland, 2008; Carozza, Langlois, Miller, &
Canfield, 2012; Fisher et al., 2012; Johnson et al., 2017)
suggests that birth defects, including nsCL/P, may have
shared aetiology with cancer. However, for nsCL/P specifi-
cally, the evidence for increased incidence of cancers among
cases and unaffected first degree relatives is largely incon-
sistent, with findings limited by available sample sizes (Bille
et al., 2005; Bjørge et al., 2008; Carozza et al., 2012; Johnson
et al., 2017; Vieira, Khaliq, & Lace, 2012; Zhu et al., 2002).
There are several practical limitations of comparing
cancer incidence in nsCL/P cases with incidence in the
general population. First, the co‐occurrence of nsCL/P
and cancer is relatively modest because of the modest
prevalence of nsCL/P (around 1 in 700; Mossey
et al., 2009), and the two phenotypes typically differ in
timing of onset. Second, cancers are highly hetero-
geneous across subtypes (e.g., childhood leukaemia and
colorectal cancer), are highly distinct and stratifying by
cancer subtype would further reduce statistical power.
Third, syndromic and nonsyndromic forms of CL/P have
different aetiologies and can be difficult to distinguish,
suggesting that combining them together could be pro-
blematic if they have differences in cancer risk.
An alternative approach to evaluating the co‐
occurrence of nsCL/P and cancer is to explore shared
genetic risk factors. Previous studies have found several
genes implicated in both nsCL/P and cancer (Dunkhase
et al., 2016), notably CDH1 (Hozyasz et al., 2014;
Machado et al., 2017; Vogelaar et al., 2012) which is
linked to gastric and breast cancer (Pharoah, Guilford, &
Caldas, 2001), and AXIN2 (Letra, Menezes, Granjeiro, &
Vieira, 2009; Letra et al., 2012; Machado et al., 2017;
Mostowska et al., 2012) which is associated with color-
ectal cancer and tooth agenesis (Liu et al., 2000; Lammi
et al., 2004). These findings suggest that common biolo-
gical pathways may influence nsCL/P and cancer risk,
but the extent to which the two phenotypes share genetic
risk factors is currently unclear.
Two methods for evaluating shared genetic risk factors
between two traits are polygenic risk scores (PRS) and
Mendelian randomization (Davey Smith & Ebrahim, 2003).
PRS are scores consisting of multiple genetic variants as-
sociated with a phenotype that can be used to evaluate
genetic overlap between two traits (Dudbridge, 2013).
Similarly, Mendelian randomization uses genetic variants
robustly associated with a trait, typically at genome‐wide
significance, in an instrumental variable framework to
evaluate possible causal relationships (Davey Smith &
Hemani, 2014). In this instance, Mendelian randomization
can be applied to test the possibility that common nsCL/P
genetic variants, a latent measure of an individual's un-
derlying liability to nsCL/P, influence cancer risk. Previous
studies have demonstrated the utility of nsCL/P PRS and
Mendelian randomization for disentangling mechanistic
relationships (Dardani et al., 2020; Howe et al., 2018, 2019).
For example, these approaches were used to provide evi-
dence of shared genetic influences between nsCL/P and
facial morphology (Howe et al., 2018).
A group of cancers that are strong candidates for shared
genetic aetiology with nsCL/P are cancers of the oral cavity
and oropharynx (OC/OPC) because of the similar anato-
mical sites affected. Major risk factors for OC/OPC include
alcohol consumption, tobacco use and human papilloma-
virus infection (IARC Working Group on the Evaluation of
Carcinogenic Risks to Humans, 2007) but OC/OPC also has
a substantial heritable component (Lesseur et al., 2016). The
possibility of shared genetic risk factors between nsCL/P
and OC/OPC has not been previously investigated, possibly
because of the relative rarity of both phenotypes.
Here, we first constructed nsCL/P PRS at a number of
different thresholds using nsCL/P genome‐wide association
study (GWAS) summary data. We then evaluated the asso-
ciation between the nsCL/P PRSs and OC/OPC using in-
dividual participant data on OC/OPC cases and controls
using data from the largest OC/OPC GWAS (Lesseur
et al., 2016) and UK Biobank. To differentiate between the
two datasets, we refer to the samples as the International
Agency for Research on Cancer (IARC) and UK Biobank
samples, respectively. We then applied Mendelian rando-
mization to both data sets to evaluate a potential causal
effect of liability to nsCL/P, a latent measure of nsCL/P
proxied by common nsCL/P variants, and OC/OPC.
Finally, we used data from UK Biobank to explore associa-
tions between nsCL/P PRS and potential shared risk factors
between nsCL/P and OC/OPC (alcohol/tobacco measures).
2 | METHODS
2.1 | Data sources
2.1.1 | Summary data from nsCL/P
GWAS meta‐analysis
We used data from two nsCL/P GWAS, which have
previously been meta‐analysed and published
2 | HOWE ET AL.
(Beaty et al., 2010; Ludwig et al., 2012; Mangold
et al., 2010). The combined summary statistics were
not publicly available, so meta‐analysis summary
statistics were reconstructed by the authors, this has
been described in detail previously (Howe et al.,
2018, 2019). In brief, a Transmission Disequilibrium
Test (TDT) was implemented in a genome wide as-
sociation study of 638 parent‐offspring trios and 178
offspring duos of European descent (Beaty
et al., 2010). The TDT results were then meta‐analysed
with GWAS summary results on 399 cases and 1,318
controls from the Bonn‐II study, also of European
descent (Mangold et al., 2010).
2.1.2 | IARC OC and OPC cancer GWAS
data set
In this study, we used a data set of OC/OPC cases and
controls which were part of a previous OC/OPC GWAS
(Lesseur et al., 2016). In brief, the data set includes 6,034
OC, oropharyngeal or hypopharyngeal cancer cases and
6,585 controls. More information on the study design,
genotyping, and phenotyping is contained in the Sup-
porting Information Methods.
For analyses, the data set was restricted to 5,048 cases
and 5,450 controls of recent European ancestry (con-
firmed by principal components analysis), which were
split into two subsamples, based on the continent of the
study centre (North America and Europe).
2.1.3 | UK Biobank
UK Biobank is a large‐scale cohort study of 502,655
participants aged between 40 and 69 years, who were
recruited from 22 recruitment centres across the
United Kingdom between 2006 and 2010. In UK
Biobank, we identified OC/OPC cases and controls
using secondary care data from Hospital Episode Sta-
tistics (HES) as well as the death and cancer registers.
For secondary analyses, we used data on self‐reported
alcohol consumption and tobacco smoking which were
collected at baseline using a questionnaire. More in-
formation on the study design, genotyping and phe-
notyping is contained in the Supporting Information
Methods.
For analyses, we used a subset of the study of 750 OC/
OPC cases and 336,319 controls, after restricting to in-
dividuals of self‐reported “White British” descent and
using kinship coefficients to remove individuals related
to the greatest number of other individuals.
2.2 | Statistical analyses
2.2.1 | The association of nsCL/P PRS
with OC/OPC in the IARC sample
nsCL/P PRS were defined using the nsCL/P meta‐
analysis GWAS summary statistics. The summary
statistics were LD clumped (r2 < .1 and 250 kb) at 11
different p value inclusion thresholds (.000001,
.000005, .00001, 0.00004, .0001, .0005, .001, .005, .01,
.05, .1) to generate sets of independent (in terms of LD)
variants in each score. The PRS was then constructed
using effect alleles and weightings based on the mag-
nitude of effect on nsCL/P of each genetic variant ta-
ken from the meta‐analysis GWAS summary statistics.
LD clumping was performed using PLINK (Purcell
et al., 2007) with the 1000 Genomes (Phase 3; Genomes
Project Consortium, 2015) CEU samples used as the
reference panel.
Next, the 11 different nsCL/P PRS were constructed
separately in the European and North American OC/
OPC case–control sample using PLINK (Purcell
et al., 2007) with an individual's PRS defined as the
sum of weights across all variants in the PRS of the
nsCL/P multiplied by the number of alleles. The asso-
ciations between the nsCL/P PRS and OC/OPC
case–control status were then estimated in the two
subsamples using logistic regression adjusting for the
first 10 genetic principal components, sex and age.
Analyses were run separately for; all cases, OC cases
only and oropharyngeal cases only (OPC). As a sensi-
tivity analysis, we additionally removed cases and
controls with less than 70% CEU ancestry. The effect
sizes, standard errors and p values from the European
and North American subsamples were meta‐analysed
using a fixed‐effects model.
2.2.2 | The association of nsCL/P PRS
with OC/OPC in UK Biobank
The UK Biobank data set was used as a follow‐up data
set for analyses in the OC/OPC GWAS data set. For
the analyses in UK Biobank, we used the nsCL/P PRS
most strongly associated with OC/OPC in the OC/
OPC GWAS data set, tested the association of this PRS
with OC/OPC. The limited number of OC/OPC
cases (N = 750) in our sample meant that it was not
possible to stratify by OC/OPC subtype, so all cases
were analysed together. All analyses were adjusted for
the first 10 genetic principal components, age,
and sex.
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2.2.3 | Mendelian randomization
analysis of liability to nsCL/P on OC/OPC
Mendelian randomization was then applied to evaluate a
causal relationship between liability to nsCL/P and
OC/OPC. As genetic instruments for liability to nsCL/P,
we used six genome‐wide significant single nucleotide
polymorphisms (SNPs), as in a previous study (Howe
et al., 2018; Ludwig et al., 2012; Table S2). Chosen variants
have large effects on nsCL/P risk (Ludwig et al., 2012)
suggesting that they can be utilised as effective genetic
instruments. Although recent nsCL/P GWAS have iden-
tified additional genome‐wide significant markers in
European populations (Leslie et al., 2017; Ludwig
et al., 2016), we were limited by available summary data.
SNP data for liability to nsCL/P were extracted from the
nsCL/P meta‐analysis GWAS summary statistics.
SNP data for OC/OPC were extracted from a meta‐
analysis of the IARC GWAS sample (European and North
American subsamples) and UK Biobank (Lesseur
et al., 2016). The GWAS in the IARC sample has been
previously described in detail (Lesseur et al., 2016). In UK
Biobank, the GWAS of 750 cases and 336,319 controls
was conducted using logistic regression in PLINK v2.00
(Purcell et al., 2007). Sex, age, and the first 10 principal
components were fitted as covariates in the model. The
GWAS summary data from all data sets were meta‐
analysed using METAL (Willer, Li, & Abecasis, 2010) to
generate combined summary statistics for OC/OPC.
We then used the TwoSampleMR (Hemani et al., 2018)
package in R to conduct Mendelian randomization analyses;
reporting the inverse‐variance weighted estimate as the pri-
mary analysis. We also used several sensitivity analyses; MR
Egger, weighted median, weighted mode and Cochran's Q
heterogeneity test (Hemani, Bowden, & Davey Smith, 2018).
2.2.4 | nsCL/P PRS, alcohol
consumption, and tobacco smoking
We tested the nsCL/P PRS (including SNPs with p<0.1) for
association with alcoholic units consumed per week and
tobacco smoking pack years. All analyses were adjusted for
sex, age and the first 10 genetic principal components.
3 | RESULTS
3.1 | nsCL/P PRS and risk of OC/OPC in
the IARC sample
We found strong evidence for an association between
nsCL/P PRS and increased risk of OC/OPC in the IARC
sample of 5,048 cases and 5,450 controls. The strongest
association was for the nsCL/P PRS including SNPs with
p< .1, where a 1 standard deviation (SD) increase in
nsCL/P PRS was associated with increased odds of
PC/OPC (odds ratio [OR]: 1.09; 95% confidence interval
[CI]: 1.04, 1.13; p= .000053). PRS with more liberal in-
clusion thresholds (e.g., p< .05 and p< .1), which in-
cluded thousands of SNPs, were more strongly associated
with risk of OC/OPC than more conservative inclusion
thresholds (Figure 1 and Table 1).
Similarly, there was strong evidence for an association
between the nsCL/P PRS and the primary OC/OPC
subtypes, oropharyngeal and OC cancer. A 1 SD increase
in nsCL/P PRS (p< 0.1) was associated with increased
odds of both oropharyngeal cancer (OR: 1.10; 95% CI:
1.04, 1.16; p= .00079) and OC cancer (OR: 1.12; 95% CI:
1.06, 1.17; p= .000016; Table S1).
3.2 | nsCL/P PRS and risk of OC/OPC in
UK Biobank
In the UK Biobank sample of 750 cases and 336,319 con-
trols, we attempted to replicate the association between
the nsCL/P PRS most strongly associated with OC/OPC in
the IARC sample (p value inclusion threshold < .1). Here,
we found no clear evidence that this PRS is associated with
increased risk of OC/OPC (OR: 1.02; 95% CI: 0.95, 1.10;
p= .55). However, confidence intervals overlapped with
the IARC sample estimate (OR: 1.09 95% CI: 1.04, 1.13)
and the meta‐analysis of the two estimates suggested evi-
dence for an association (OR: 1.07; 95% CI: 1.03, 1.11;
p= .0009).
3.3 | Mendelian randomization:
Liability to nsCL/P and risk of OC/OPC
Using combined GWAS summary data from the IARC
and UK Biobank samples, 5,798 cases and 341,769 con-
trols, we found little evidence for an effect of liability to
nsCL/P on OC/OPC; a 1‐unit log odd increase in liability
to nsCL/P was not strongly associated with OC/OPC (MR
IVW: OR: 0.99; 95% CI: 0.95, 1.05; p= .84). Mendelian
randomization sensitivity analyses generated consistent
effect estimates (Table 2).
3.4 | nsCL/P PRS, alcohol consumption
and tobacco smoking
To evaluate whether shared genetic effects could relate to
interactions of the nsCL/P PRS with shared
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environmental risk factors we investigated the genetic
overlap between the PRS and measures of alcohol con-
sumption and tobacco smoking in UK Biobank. Again,
we used the nsCL/P PRS most strongly associated with
OC/OPC in the IARC sample (p< 0.1). We did not find
strong evidence that the nsCL/P PRS was associated with
any of the measures tested. A 1 SD increase in nsCL/P
PRS corresponded to a −0.02 pack year decrease in life-
time smoking (95% CI: −0.07, 0.03; p= .46; N= 284,144)
and a −0.05 units per week decrease in alcohol use (95%
CI: −0.11, 0.01; p= .11; N= 336,026).
4 | DISCUSSION
In this study, we found some evidence to suggest that
nsCL/P PRS are associated with modestly increased risk
of OC/OPC. Follow‐up Mendelian randomization ana-
lyses using well established nsCL/P risk SNPs as a latent
measure of nsCL/P suggested no consistent association
between key common nsCL/P variants and OC/OPC.
These findings are consistent with our initial hypothesis
that nsCL/P and OC/OPC share some genetic risk factors
as opposed to the possibility of a causal relationship,
which has previously been demonstrated for nsCL/P and
philtrum width (Howe et al., 2018).
The specific shared genetic influences and relevant
biological pathways that may have induced the association
between the nsCL/P PRS and OC/OPC are currently un-
clear. While the Mendelian randomization approach in-
cludes only replicated variants with strong associations,
the PRS approach is much more liberal and will include
many variants with weaker associations. The increased
variation explained by the PRS approach comes with the
caveat that many variants of small effects will be included
which have less clear direct relevant to nsCL/P. The in-
terpretation of what a PRS is proxying for becomes in-
creasingly complex as the number of SNPs included in the
FIGURE 1 Association of nsCL/P PRS with OC/OPC in the International Agency for Research on Cancer sample. A forest plot
showing the associations between different nsCL/P PRS, ranging from 10 SNPs to over 10,000 SNPs, and OC/OPC risk. nsCL/P,
nonsyndromic cleft lip/palate; OC, oral cavity; OPC, oropharynx; PRS, polygenic risk score; SNP, single nucleotide polymorphism










against controls (5,048 cases
and 5,450 controls)
OR (95% CI) per 1
SD increase
in PRS p Value
.000001 10 1.01 (0.97, 1.05) .64
.000005 15 1.02 (0.98, 1.07) .27
.00001 18 1.02 (0.98, 1.07) .27
.00005 48 1.01 (0.97, 1.05) .71
.0001 78 1.01 (0.97, 1.05) .58
.0005 238 1.01 (0.97, 1.05) .71
.001 424 1.01 (0.96, 1.05) .79
.005 1,607 1.05 (1.01, 1.09) .021
.01 2,777 1.03 (0.99, 1.08) .10
.05 8,620 1.06 (1.02, 1.11) .0026
.1 12,614 1.09 (1.04, 1.13) .000053
Abbreviations: CI, confidence interval; nsCL/P, nonsyndromic cleft
lip/palate; OC, oral cavity; OPC, oropharynx; PRS, polygenic risk score;
SD, standard deviation; SNP, single nucleotide polymorphism.
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score increases. Indeed, the nsCL/P PRS most strongly
associated with OC/OPC included over 10,000 SNPs. One
possibility is that the genetic overlap may be attributable to
certain genes being involved both in early development
and tumour suppression. For example, the CDH1 gene,
thought to be related to nsCL/P and cancer subtypes, has
been shown to be related to both axonal growth and pat-
terning in the developing murine brain (Konishi, Steg-
müller, Matsuda, Bonni, & Bonni, 2004), and tumour
suppression (Berx, Becker, Höfler, & Van Roy, 1998).
Another possibility is that the nsCL/P PRS may cap-
ture environmental influences relating to both nsCL/P
and cancer risk. Maternal behaviour such as cigarette
smoking and alcohol consumption have been hypothe-
sised to influence nsCL/P risk and both are established
risk factors for OC/OPC. Given that the maternal geno-
type is correlated with the offspring genotype, it is plau-
sible that nsCL/P PRS could capture effects of maternal
environmental factors. The foetal genotype may also play
an important role in the effect of environmental ex-
posures on risk of orofacial clefts. For example, there is
some evidence that the maternal and foetal ADH1C
haplotype may modify the association between maternal
alcohol consumption and risk of orofacial clefts via al-
cohol metabolism (Boyles et al., 2010). We did not find
strong evidence that nsCL/P PRS are associated with al-
cohol and cigarette use in UK Biobank but were unable to
test pathways relating to metabolism.
The findings of this study are consistent with previous
genetic studies that have found evidence of loci asso-
ciated with both nsCL/P and various cancer subtypes
(Dunkhase et al., 2016; Hozyasz et al., 2014; Letra
et al., 2009, 2012; Machado et al., 2017; Mostowska
et al., 2012; Vogelaar et al., 2012). Our results are also
consistent with a previous study exploring adult‐onset
cancers in nsCL/P cases, which was underpowered to
detect a modest effect (Bille et al., 2005).
This study is the first to investigate the genetic over-
lap between nsCL/P and OC/OPC. Previous epidemiolo-
gical and genetic studies have explored the relationship
between nsCL/P and all cancers, however, cancers aris-
ing from different organs may be aetiologically hetero-
geneous. Although similar results were found in analyses
for the OC and OPC subtype analyses with these subtypes
also aetiologically heterogeneous. In Western popula-
tions, smoking and alcohol are established risk factors for
both OC and OPC, while HPV status is thought to be a
risk factor for OPC only (Lesseur et al., 2016). Future
work could evaluate genetic overlap between nsCL/P and
other cancer subtypes to determine if the association is
consistent across other cancer subtypes or localised spe-
cifically to oral tissues.
The use of a PRS as a genetic proxy for nsCL/P in our
analyses is a considerable strength. PRS analyses have
advantages over candidate gene or candidate SNP ap-
proaches used in previous studies (Dunkhase et al., 2016;
Hozyasz et al., 2014; Letra et al., 2009, 2012; Machado
et al., 2017; Mostowska et al., 2012; Vogelaar et al., 2012)
because of the reduction in the number of statistical tests,
and the potential to extend the evidence of genetic
overlap at specific loci to examine genome‐wide genetic
overlap. Although the nsCL/P GWAS data set was mod-
estly sized, the construction of nsCL/P PRS in a much
larger OC/OPC GWAS data set meant that analyses were
well‐powered to detect a modest genetic overlap.
Nevertheless, there are several limitations of this
study. First, the lack of a convincing replication of the
PRS analysis in UK Biobank weakens the argument for
genetic overlap between the two phenotypes. However,
this may be because of the modest number of OC/OPC
cases in the UK Biobank, with confidence intervals
overlapping between the two studies. Second, the
OC/OPC GWAS data set was highly ancestrally hetero-
geneous and included samples from 12 different
TABLE 2 Mendelian randomization
analysis of liability to nsCL/P on
OC/OPC risk
Test Interpretation OR (95% CI) p Value
Inverse variance weighted Primary resulta 0.99 (0.95, 1.05) .84
Heterogeneity of inverse
variance weighted
Balanced pleiotropy N/A .59





Regression estimatea 0.99 (0.87, 1.13) .69
Weighted median Consistencya 0.99 (0.93, 1.06) .77
Weighted mode Consistencya 0.99 (0.92, 1.06) .71
Abbreviations: CI, confidence interval; nsCL/P, nonsyndromic cleft lip/palate; OC, oral cavity; OPC,
oropharynx; OR, odds ratio.
aUnits: odds ratio for OC/OPC perper 1‐unit log odd increase in liability to nsCL/PnsCL/P.
bUnits: average pleiotropic effect of a nsCL/P genetic variant on odds of OC/OPC.
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epidemiological studies, including a case‐only study (the
Head and Neck 5000). Therefore, it is possible that allele
frequency differences between cases and controls relating
to population differences could result in spurious asso-
ciations with the nsCL/P PRS, although this is unlikely
given the number of SNPs in the PRS. Third, with in-
sufficient genetic instruments for OC/OPC, we did not
perform a bidirectional Mendelian randomization ana-
lysis so cannot rule out the possibility that OC/OPC
variants consistently affect nsCL/P risk. Fourth, we were
unable to run stratified analysis investigating the possi-
bility of heterogeneity between HPV and non‐HPV driven
tumours. Fifth, in this study we treated nsCL/P subtypes
(cleft lip with cleft palate, cleft lip only) homogeneously
despite growing evidence that they are aetiologically
distinct (Leslie et al., 2017; Ludwig et al., 2016; Sharp
et al., 2017). This complicates the interpretation of the
results because the OPC includes the soft palate while the
OC includes the lips and hard palate. It is therefore,
possible that the different nsCL/P subtypes may have
different mechanistic relationships with the OC/OPC
subtypes. Finally, we were unable to explore the effects of
somatic mutations in the oral tissues which could influ-
ence both orofacial cleft risk and localized cancer.
To conclude, we found some evidence of shared ge-
netic influences on nsCL/P and OC/OPC unrelated to
alcohol or tobacco intake. Follow‐up analyses, potentially
using additional datasets such as the Cleft Collective
(www.bristol.ac.uk/dental/cleft-collective/), are required
to investigate the possible common biological pathways
between nsCL/P and OC/OPC, and to evaluate possible
mechanistic relationships between nsCL/P and cancer
subtypes affecting distinct areas to orofacial clefts.
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